AR118778A1 - Formulación de anticuerpo - Google Patents

Formulación de anticuerpo

Info

Publication number
AR118778A1
AR118778A1 ARP200101166A ARP200101166A AR118778A1 AR 118778 A1 AR118778 A1 AR 118778A1 AR P200101166 A ARP200101166 A AR P200101166A AR P200101166 A ARP200101166 A AR P200101166A AR 118778 A1 AR118778 A1 AR 118778A1
Authority
AR
Argentina
Prior art keywords
antibody formulation
subject
symptoms
administering
agent
Prior art date
Application number
ARP200101166A
Other languages
English (en)
Inventor
John Simard
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of AR118778A1 publication Critical patent/AR118778A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Los síntomas de la dermatitis atópica en un sujeto humano se reducen mediante la administración al sujeto de una composición farmacéutica que incluye un portador farmacéuticamente aceptable y una cantidad terapéuticamente efectiva de un agente que selectivamente se une a IL-1a.
ARP200101166A 2019-04-24 2020-04-24 Formulación de anticuerpo AR118778A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962837942P 2019-04-24 2019-04-24

Publications (1)

Publication Number Publication Date
AR118778A1 true AR118778A1 (es) 2021-10-27

Family

ID=72941830

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200101166A AR118778A1 (es) 2019-04-24 2020-04-24 Formulación de anticuerpo

Country Status (6)

Country Link
US (1) US20220220196A1 (es)
EP (1) EP3958903A4 (es)
JP (1) JP2022530063A (es)
AR (1) AR118778A1 (es)
TW (1) TW202106711A (es)
WO (1) WO2020219506A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024130541A1 (zh) * 2022-12-20 2024-06-27 成都优洛生物科技有限公司 一种靶向IL-1α的抗体或其抗原结合片段及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103044550A (zh) * 2006-09-01 2013-04-17 津莫吉尼蒂克斯公司 Il-31单克隆抗体的可变区序列和使用方法
HUE052220T2 (hu) * 2006-09-08 2021-04-28 Abbvie Bahamas Ltd Interleukin-13 kötõfehérjék
WO2012088094A2 (en) * 2010-12-21 2012-06-28 Abbott Laboratories Il-1 binding proteins
CA3098148A1 (en) * 2018-04-24 2019-10-31 Janssen Biotech, Inc. Treatment of atopic dermatitis

Also Published As

Publication number Publication date
EP3958903A4 (en) 2023-08-02
EP3958903A1 (en) 2022-03-02
JP2022530063A (ja) 2022-06-27
US20220220196A1 (en) 2022-07-14
TW202106711A (zh) 2021-02-16
WO2020219506A1 (en) 2020-10-29

Similar Documents

Publication Publication Date Title
MA47313A (fr) Formulations sous-cutanées d'anticorps her2
CL2016002585A1 (es) Inmunoconjugado que comprende una proteína de unión a antígeno que se une a antígeno de maduración de linfocitos b (bcma) y un agente citotóxico, composición farmacéutica y su uso (divisional solicitud 201303373)
PH12020551726A1 (en) Treatment of atopic dermatitis
AR053651A1 (es) Tratamiento combinado de anticuerpo antictla4 r inhibidor de aromatasa para el cancer de mama
CL2008001984A1 (es) Formulacion de anticuerpo anti-cd20; y su uso para tratar enfermedades que implican celulas que expresan cd20 en un mamifero.
ECSP22083269A (es) ANTICUERPOS MONOCLONALES HUMANOS DIRIGIDOS CONTRA EL CORONAVIRUS 2 DEL SÍNDROME RESPIRATORIO AGUDO GRAVE (SARS-CoV-2)
AR073717A1 (es) Anticuerpos anti-notch2 de murino y humano, y metodos de uso
AR080795A1 (es) Anticuerpos anti-lrp6 (proteina relacionada con el receptor ldl tipo 6)
BR112018000212A2 (pt) uso combinado de anticorpos anti pd-1 e anti m-csf no tratamento de câncer
PA8809601A1 (es) Combinación anti-retroviral
ECSP22080714A (es) Anticuerpos que se unen a b7h4
AR108889A1 (es) Combinaciones para el tratamiento del cáncer
CL2018001334A1 (es) Anticuerpos y conjugados anticuerpo-fármaco anti-5t4.
CO6630117A2 (es) Anticuerpos contra cxcr4
UY38748A (es) Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3
PH12019501900A1 (en) Treatment of hidradenitis suppurativa
CL2018000131A1 (es) Inmunoconjugados de il22
CR20220355A (es) Compuestos activos frente a receptores nucleares
CL2021000924A1 (es) Uso de reboxetina para el tratamiento de narcolepsia
AR118778A1 (es) Formulación de anticuerpo
MX2022007265A (es) Compuestos activos frente a receptores nucleares.
CL2023001432A1 (es) Anticuerpos de cadena pesada que se unen al receptor de folato alfa
MX2023011848A (es) Tratamientos contra el prurigo nodular.
ECSP22021881A (es) Composición farmacéutica acuosa de anticuerpo anti-pd1 prolgolimab y su uso
CO2018013792A2 (es) Regímenes de dosificación de vortioxetina para el rápido inicio del efecto antidepresivo